New treatment option for active lupus nephritis!
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Recent Posts
Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Survival
What is the impact of Enhertu breast cancer treatment for patients with early-stage HER2-positive breast cancer? Enhertu breast cancer treatment has shown a significant improvement in invasive disease-free survival (iDFS) compared to the prior standard, trastuzumab emtansine (T-DM1). According to...
Transforming Healthcare with the Gene Therapy Access Model
The gene therapy access model is a groundbreaking federal-state collaborative framework designed to improve how transformative treatments are distributed and financed, particularly within Medicaid. This innovative approach answers a key question for patients and policymakers: How can we ensur...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
Are you searching for effective Sanofi insulin savings options to manage diabetes medication costs in 2025? The Sanofi Patient Connection Savings Registration program offers an efficient pathway for eligible patients to save on key insulin products—helping reduce out-of-pocket expenses and promot...